Robert Stadelman

Title: The Innovations of Robert Stadelman

Introduction

Robert Stadelman is an accomplished inventor based in New Market, MD (US). He has made significant contributions to the field of biotechnology, particularly in the production of recombinant Adeno-Associated Virus (rAAV) particles. His innovative methods have the potential to advance gene therapy techniques and improve treatment options for various diseases.

Latest Patents

Stadelman holds a patent for a "Scalable method for recombinant AAV production." This patent outlines improved methods for producing rAAV particles. The method involves culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor. Additionally, it includes the use of an increased amount of a sodium salt to enhance production efficiency. Stadelman's patent is a testament to his expertise and dedication to advancing biotechnological methods.

Career Highlights

Stadelman is currently associated with Regenxbio Inc., a company known for its innovative approaches in gene therapy. His work at Regenxbio has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research. With a total of 1 patent, Stadelman has established himself as a key figure in the biotechnology sector.

Collaborations

Stadelman has worked alongside talented individuals such as Michael Gillmeister and Miguel Valle. These collaborations have fostered an environment of innovation and creativity, leading to advancements in their shared field of expertise.

Conclusion

Robert Stadelman's contributions to the field of biotechnology, particularly through his patent for scalable rAAV production methods, highlight his role as an influential inventor. His work continues to pave the way for advancements in gene therapy and related technologies.